Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets
![](https://nationalhealthmirror.com/wp-content/uploads/2021/11/Zydus-Cadilas-U.S.-subsidiary-Zydus-Pharmaceuticals-1024x757.jpg)
![](https://nationalhealthmirror.com/wp-content/uploads/2021/11/Zydus-Cadilas-U.S.-subsidiary-Zydus-Pharmaceuticals-1024x757.jpg)
NEW DELHI: Zydus Cadila’s U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Eluxadoline Tablets in the strengths of 75 mg and 100 mg (US RLD: VIBERZI Tablets).
Zydus’ Eluxadoline Tablets are indicated in adults for the treatment of irritable bowel syndrome with diarrhea, or IBS-D. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.